Manilam Industries (MANILAM)
Slow GrowerScore breakdown: P/E: 2/3 · ROCE: 1/2 · Growth: 0/2 · Dividend: 0/1
Key Financials
| Current Price | ₹54.5 |
| Market Cap | ₹114.59 Cr |
| P/E Ratio | 15.57 |
| ROCE | 17.42% |
| ROE | —% |
| Dividend Yield | 0% |
| Profit Growth | 0% |
| Debt/Equity | — |
| Sales Growth | 0% |
| 52-Week Range | ₹41.5 — ₹67 |
Strengths
- Moderate valuation: P/E of 15.57 on a ₹115 Cr market cap is not excessively demanding for a profitable company.
- ROCE of 17.42% indicates a reasonably efficient use of capital employed.
- Latest quarter is profitable with sales of ₹60 Cr and net profit of ₹3 Cr.
- Current price of ₹54.50 sits above the 52-week low of ₹46.00, showing some market support.
Concerns
- Piotroski F-Score of 3/9 signals weak fundamental health and possible financial stress.
- Sales growth and profit growth are both 0.00%, with no dividend yield to compensate shareholders.
- Critical data missing: book value, debt/equity, and promoter holding are unavailable, so margin of safety cannot be assessed.
- Net profit margin of roughly 5% on latest quarterly sales is thin and leaves little room for downturns.
AI Analysis
Look at Manilam Industries and I am reminded of Graham's warning: the investor's chief problem is himself. The market prices it at ₹54.50, a ₹115 Cr market cap, and a P/E of 15.57. That is not an obvious bargain, but neither is it expensive. Latest quarter shows sales of ₹60 Cr and net profit of ₹3 Cr; if that is indicative, profit margins are thin, around 5%. ROCE of 17.42% is respectable, and it tells me the existing capital base earns a decent return. But a 3-out-of-9 Piotroski F-Score is a red flag: fundamental health is weak, with possible deterioration in profitability, leverage, or efficiency. Sales and profit growth are both 0.00%, dividend yield is 0.00%, and I have no book value, no debt/equity, and no promoter holding data. This is not the kind of business I can confidently project ten years out. Without a visible moat or reliable growth, I cannot call it a great compounding machine. It looks more like a slow grower, or possibly a business whose future depends on capital allocation and industry conditions I cannot see. At this price, I would need a much stronger balance sheet and evidence of earned, fundable growth. For a Graham-style investor, the absence of data is itself a fact: if the numbers are not available, I cannot compute a margin of safety. I would wait on the sidelines, watching for fuller disclosure and for the operating score to improve before committing capital.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer